Danacioglu YO, Keser F, Ersoz C, et al. - In pediatric patients with neurogenic bladders (NB) due to myelomeningocele (MMC), researchers sought to determine the efficacy of intradetrusor injections of onabotulinum toxin-A (BoNT-A). Using logistic regression analysis, the factors predicting success were also assessed. Sixty-two patients with NB due to MMC who underwent intravesical BoNT-A injection (100–300 U) between May 2013 and December 2018 were identified retrospectively. Data reported that the mean age of the children was 9 ± 3.36 years and the mean follow-up was 28.5 ± 12.2 months. It was noted that the mean maximal cystometric capacity increased from 172.4 ± 45.6 mL to 236.3 ± 67.2 mL. Intradetrusor BoNT-A injections in children with NB refractory to conservative therapy provide excellent results, as clinical success was achieved in 64.5% of the patients. In patients who had low-compliant bladders without detrusor overactivity, poor responses were noted.